Samyang Biopharm Corporation
KKRX:0120G043,500.00
KRW
-750.00
(-1.69%)
ISIN
KR70120G0001
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Kyung-Jin Kim
- Full Time Employees
- 407
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seongnam-si South Korea
- Website
- samyangbiopharm.com
- Similar Companies
- Business
- Samyang Biopharm Corporation is a South Korea-based biopharmaceutical and medical technology company that develops, manufactures, and commercializes specialty oncology therapeutics, biodegradable medical devices, aesthetic medicine solutions, and nucleic acid drug delivery platforms. The company operates through three core business segments: Medical Devices, Pharmaceuticals, and Gene Therapeutics. Its medical device portfolio comprises synthetic biodegradable surgical sutures, including polyglycolic acid, polydioxanone, and polyglactin formulations marketed under the Monofix brand; oxidized regenerated cellulose-based absorbable hemostats; bioresorbable anti-adhesion barriers; surgical hernia meshes; and medical aesthetic products, including Croquis polydioxanone (PDO) thread-lifting sutures and Lafullen polycaprolactone (PCL) aesthetic dermal fillers. In pharmaceuticals, the company manufactures and sells cytotoxic anticancer injectables; polymeric micelle paclitaxel formulations under the Genexol and Genexol-PM brand names; specialty treatments for solid tumors and hematologic malignancies; and Contract Development and Manufacturing Organization (CDMO) services for sterile injectables. Its gene therapeutics division develops proprietary tissue-selective drug delivery systems, notably the SENS (Selectivity Enabling Nano Shell) and NanoReady platforms, designed for the targeted intracellular delivery of messenger RNA (mRNA) and small interfering RNA (siRNA) payloads in cancer vaccines and rare disease indications. Founded in 1995 as the pharmaceutical division of Samyang Corporation, the company is headquartered in Seongnam-si, Gyeonggi-do, South Korea, and serves healthcare providers, clinical institutions, and corporate partners across Asia, Europe, and North America, supported by an oncology research subsidiary, Samyang Biopharm USA, Inc., in Cambridge, Massachusetts, and a surgical suture manufacturing facility in Gödöllő, Hungary. In recent major developments, the company was spun off from Samyang Holdings and independently listed on the Korea Exchange under ticker 0120G0 in November 2025 to accelerate its gene therapy pipeline and global CDMO expansion. Operationally, the company expanded its cGMP- and EU-GMP-compliant cytotoxic injectable production facilities at its Daejeon manufacturing site, scaled European production at its Hungarian suture plant, broadened international commercial distribution for its Lafullen aesthetic filler, and entered strategic research alliances, including a co-development partnership with LG Chem to engineer mRNA-based oncology therapeutics utilizing SENS drug delivery technology.